Cambrex Invests $120 Million to Boost U.S. API Manufacturing and Peptide Production

Cambrex is investing $120 million to enhance U.S. API manufacturing and peptide production, responding to rising demand in the pharmaceuticals sector and supporting the reshoring trend.

• Cambrexs $120 million investment will expand its operations in the U.S., specifically in Charles City, Iowa, to meet the growing demand for API development and manufacturing.
• The funding will accelerate Cambrexs capabilities in Peptide production, a key area in the fast-growing peptide therapeutics market, enhancing their competitive edge.
• This initiative aligns with a national trend where customers are working with federal and state agencies to reshore Medication manufacturing, strengthening the domestic supply chain.